Evidence map›Paper›PMID 37111363›Full record

ReviewPharmaceuticals (Basel, Switzerland)2023

PET Imaging in Bladder Cancer: An Update and Future Direction.

Jules Zhang-Yin, Antoine Girard, Etienne Marchal, Thierry Lebret, Marie Homo Seban, Marine Uhl, Marc Bertaux

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. European journal of nuclear medicine and molecular imaging · 2025
    Article
  4. Bladder (San Francisco, Calif.) · 2025
    Article
  5. Pre-Hydration and a Forced Diuresis Protocol forJournal of clinical medicine · 2024
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Jules Zhang-YinDepartment of Nuclear Medicine, Clinique Sud Luxembourg, Vivalia, B-6700 Arlon, Belgium.ORCID 0000-0001-8451-2094
Antoine GirardDepartment of Nuclear Medicine, Amiens-Picardy University Hospital, 80054 Amiens, France.
Etienne MarchalDepartment of Nuclear Medicine, Amiens-Picardy University Hospital, 80054 Amiens, France.
Thierry LebretDepartment of Urology, Foch Hospital, 92150 Suresnes, France.
Marie Homo SebanDepartment of Nuclear Medicine, Foch Hospital, 92150 Suresnes, France.
Marine UhlDepartment of Urology and Renal Transplantation, Amiens-Picardy University Hospital, 80054 Amiens, France.
Marc BertauxDepartment of Nuclear Medicine, Foch Hospital, 92150 Suresnes, France.ORCID 0000-0001-9954-8866
Centre Hospitalier Universitaire Amiens-Picardie · FRHôpital Foch · FRCliniques du Sud Luxembourg · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular imaging with positron emission tomography is a powerful tool in bladder cancer management. In this review, we aim to address the current place of the PET imaging in bladder cancer care and offer perspectives on potential future radiopharmaceutical and technological advancements. A special focus is given to the following: the role of [

Indexed as

2-[18F]fluoro-2-deoxy-D-glucosebladder cancerpositron emission tomography

Identifiers

PMID37111363
PMCPMC10144644
OpenAlexW4366188473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.